NAGE
Niagen Bioscience Inc.

3,460
Mkt Cap
$414.99M
Volume
1.13M
52W High
$14.69
52W Low
$5.05
PE Ratio
21.36
NAGE Fundamentals
Price
$5.17
Prev Close
$5.13
Open
$5.20
50D MA
$6.35
Beta
1.38
Avg. Volume
811,872.55
EPS (Annual)
$0.1094
P/B
5.86
Rev/Employee
$957,663.46
Loading...
Loading...
News
all
press releases
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Niagen Bioscience (NASDAQ:NAGE) Shares Down 3.4% - Here's What Happened
Niagen Bioscience (NASDAQ:NAGE) Stock Price Down 3.4% - Time to Sell...
MarketBeat·10d ago
News Placeholder
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen, the Leading NAD+ Supplement in the U.S.*
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it has partnered with...
Business Wire·24d ago
News Placeholder
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are covering the firm, Marketbeat reports. One...
MarketBeat·1mo ago
News Placeholder
Precision Wealth Strategies LLC Makes New $1.53 Million Investment in Niagen Bioscience, Inc. $NAGE
Precision Wealth Strategies LLC bought a new stake in Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) in the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·1mo ago
News Placeholder
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queens University Belfast
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a...
Business Wire·2mo ago
News Placeholder
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Moderate Buy" from Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat...
MarketBeat·2mo ago
News Placeholder
Niagen Bioscience (NASDAQ:NAGE) CFO Acquires 4,465 Shares
Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) CFO Ozan Pamir bought 4,465 shares of the stock in a transaction dated Friday, November 14th. The stock was bought at an average price of $6.81...
MarketBeat·3mo ago
News Placeholder
Niagen Bioscience Launches Tru Niagen Beauty The First NAD+ Skincare Supplement in the U.S. Featuring Niagen (Patented Nicotinamide Riboside)
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Tru Niagen Beauty...
Business Wire·3mo ago
News Placeholder
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the...
Business Wire·3mo ago
<
1
2
...
>

Latest NAGE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.